New Korus technology tuned to transform industry standards in cell elution and washing

Innovations in cell processing are very much needed to improve the development of the process and productivity of GMP production and to ensure a sufficiently high yield for viable therapy. Developers can now accelerate clinical development, scale effectively and be ready to be the first on the market with Invetech’s new Korus system.

“To accelerate the commercialization of cellular and gene therapies, our industry needs efficient and scalable manufacturing technologies that can provide high-quality therapies cost-effectively,” he said. Andreas Knaak, President of Inveteh. “Invetech’s new technology offering, as demonstrated by our new Korus system, is our ongoing commitment to helping life-saving therapies become more accessible to more patients.”

Invetech’s Korus system uses a gentle washing process to provide a cleaner cell population for cell therapy production. The results of the study show a transformative change in the processing of raw materials compared to current industry standards, which will lead manufacturers to succeed downstream.

Compared to standard washing protocols, Korus can be obtainedand in:

– 31% purer lymphocyte population
– 49% improvement in T cell recovery after selection
– 70% more T cells during expansion
– 2.5X improvement in production yield

Integrating Korus technology into the production process of cell therapy can lead to better downstream productivity, including significantly higher recovery of target cells during selection and significantly higher cell growth during expansion. The 2.5X improvement in production yield means that cell therapy developers can expect to more consistently grow enough cells for a viable cell therapy end product.

During testing in the above internal study, similar lymphocyte recovery efficiency was observed in the Korus ™ and CS5 + control arms (washing), despite the increase in purity in the Korus arm due to elution. The relative recovery of Korus T cell selection and the proliferation of folds are significantly higher, resulting in over 70% more cells cultured in the Korus arm.

John Ellis, who leads Invetech ‘s cell therapy science and applications team, explains the results of Korus’ testing program. “The production efficiency of cell therapies needs to be improved and innovated if the cell therapy industry achieves its commercialization goals. Our data show that while achieving recovery of lymphocyte cells from apheresis, similar to the control wash process, Korus elutes lymphocytes to high purity, leading to improvements in downstream performance, including greater recovery of Dynabead cell selection and expansion. of folding. “

“Overall, this innovation in cell processing will reduce the impact of the variability of the starting material, contribute to higher production yields and reduce the risk of batch failure; and will potentially reduce the cost of goods for future therapies. “

The Korus system is for research, laboratory or further production only. It is not intended for medical use in therapeutic or diagnostic procedures. Clients are responsible for validating the use of Korus as part of their process or therapy.

About Inveteh

Invetech helps cellular and gene therapy developers visualize, strategize and manage the future. Through ready-to-use systems, customized solutions and full-service services, we are rapidly accelerating vital, emerging therapies from the clinic to commercial-scale production. Together with our partners, we are expanding the range of next-generation medical achievement that is revolutionizing healthcare.

Additional information about the press

Paul Dal Pozzo
Senior Product Manager
Inveteh
[email protected]
+ 1 720 822 3709

Еева Рутио
Marketing manager, brand and thought leadership
Inveteh
[email protected]
+ 1 858 688 7136

Related links: invetechgroup.com/korus

and The full comparative study can be found here.

SOURCE Inveteh

Leave a Comment

Your email address will not be published.